Notable 52-Week Highs and Lows of the Day 09/13: (CUR) (SNSS) (KEY) High; (MKTS) (SAPX) (CRTX) Low
- Advanced Micro Devices (AMD) Cuts Q2 Outlook
- Horizon Pharma (HZNP) Proposes to Acquire Depomed (DEPO) for $29.25/Share
- Deutsche Bank Downgrades Tesla Motors (TSLA) to Hold on Valuation
- After-Hours Stock Movers 07/06: (SUNE) (AAP) (CTCT) Higher; (AMD) (SHLM) (ETRM) Lower (more...)
- Trading Reaction in Aetna (AET) and Humana (HUM) Post Deal Offers 'Strong Buying Opportunity', Leerink Partners Says
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.
- Neuralstem, Inc. (AMEX: CUR) high of $1.96. Neuralstem ripping today following data from a study of NSI-566 on rats, showing the animals recovered significant locomotor function, regaining movement in all lower extremity joints, and that the transplanted neural stem cells turned into neurons which grew a "remarkable" number of axons that extended for "very long distances" over 17 spinal segments, making connections both above and below the point of severance.
- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) high of $4.12. Continuing higher from Wednesday, when the pharma said it would implement a one-time, 225-patient sample size increase to its Phase 3 VALOR trial of vosaroxin in acute myeloid leukemia (AML), bringing target enrollment to 675 patients.
- KeyCorp (NYSE: KEY) high of $8.85. KeyCorp higher following the FOMC move to start open-market purchases of MBS at the rate of $40 billion per month, keeping doing so until unemployment is restored, and also continue with Operation Twist. Many financials are popping on the session as a result.
- Yamana Gold, Inc. (NYSE: AUY) high of $18.44. Yamana ripping on FOMC news as well, as demand for gold will increase as dollar-denominated contracts cheaper on devaluation of the U.S. dollar with more easing. Shares are up about 5.2 percent on the session.
- Direct Markets Holdings Corp. (Nasdaq: MKTS) low of $0.08. Direct Markets broker-dealer subsidiary, Rodman & Renshaw, LLC, advised the Financial Industry Regulatory Authority that it was no longer in compliance with the SEC’s Net Capital Rule 15c3-1, and, accordingly, that such subsidiary would cease conducting its securities business, other than liquidating transactions, unless and until it can achieve compliance with the rule. The broker-dealer is exploring all options, including the filing of a Form BDW to terminate its broker-dealer license and the sale of certain of its assets to affiliated or unaffiliated parties including an entity controlled by Michael Vasinkevich, a founder of the Registrant and its former vice chairman.
- Seven Arts Entertainment, Inc. (Nasdaq: SAPX) low of $0.52. Shares of Seven Arts just falling below a 70 cent support level seen over the last few weeks.
- Cornerstone Therapeutics Inc. (Nasdaq: CRTX) low of $3.10. Cornerstone announced today the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) of the U.S. Food and Drug Administration (FDA) recommended against the approval of the Company's New Drug Application (NDA) for lixivaptan (CRTX 080) for the treatment of symptomatic hypervolemic and euvolemic hyponatremia associated with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH), respectively.
Shares were halted earlier, then tumbled 52 percent to the new mark on resumption.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EnteroMedics (ETRM) Prices 32M Common Stock, Warrants Unit Offering at 50c/Unit
- Aimsi Technologies (AIMT) Files $115M COmmon Stock IPO
- NextEra Energy Partners (NEP) Files 2.6M Common Units Shelf for Selling Unitholders
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesFederal Open Market Committee, Rodman & Renshaw
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!